TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors

Launched by TIANJIN MEDICAL UNIVERSITY CANCER INSTITUTE AND HOSPITAL · Jun 27, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for patients with liver tumors that cannot be surgically removed, specifically hepatocellular carcinoma (HCC), cholangiocarcinoma, and other liver malignancies. The researchers are looking at how well a combination of a procedure called TACE (which delivers chemotherapy directly to the liver) and immune checkpoint inhibitors (a type of drug that helps the immune system fight cancer) works together to treat these conditions. The trial is currently recruiting participants aged 18 and older who have a confirmed diagnosis of HCC and are eligible for TACE treatment, among other criteria.

If you decide to participate, you will need to sign a consent form and will be carefully screened to ensure you meet the eligibility requirements. It’s important to note that certain health conditions, such as heart disease or a history of kidney problems, may exclude you from the trial. Participants will receive the combined treatment and will be monitored for its effectiveness and any possible side effects. This could be a valuable opportunity for patients seeking new options to manage their liver cancer, but it’s essential to discuss with your healthcare provider whether this trial is right for you.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Confirmed diagnosis of HCC by histology/ cytology or clinical criteria
• • Sign informed consent
• • When screening for age, the age should be ≥ 18 years old
• • Eligible for TACE treatment
• • ECOG physical condition score is 0 or 1
• • No prior systemic therapy for HCC, especially immunotherapy
• • According to the following mRECIST criteria, at least one measurable intrahepatic lesion is suitable for repeated evaluation
• Exclusion Criteria:
• • Have any history of kidney disease or nephrotic syndrome
• • Evidence of extrahepatic spread (EHS)
• • Cardiovascular diseases with clinical significance (such as activity), including unstable angina, ≥ grade 2 congestive heart failure, and arrhythmia with poor drug treatment control
• • Any condition representing a contraindication to TACE as determined by the investigators
• • Known genetic factors for bleeding or thrombosis; Any previous or current evidence indicating a tendency for bleeding
• • Individuals who have received immunotherapy (anti PD-1, anti PD-L1, or anti CTLA-4 treatment)
• • Previously received HAIC (hepatic artery infusion chemotherapy), TACE (hepatic artery chemoembolization), TAE (hepatic artery embolization), or TARE (hepatic artery radiation embolization)
• • Previously received systemic anti-cancer treatment for HCC ,ICC or liver metastasis.